{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:22:11Z","timestamp":1791685331293,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31870786"],"award-info":[{"award-number":["31870786"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773557"],"award-info":[{"award-number":["81773557"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073690"],"award-info":[{"award-number":["82073690"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007046","name":"Wuhan University","doi-asserted-by":"publisher","award":["KYPT-ZD-9"],"award-info":[{"award-number":["KYPT-ZD-9"]}],"id":[{"id":"10.13039\/501100007046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2042020kf1043"],"award-info":[{"award-number":["2042020kf1043"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.bmc.2021.116185","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T04:47:27Z","timestamp":1619844447000},"page":"116185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Novel hybrid conjugates with dual estrogen receptor \u03b1 degradation and histone deacetylase inhibitory activities for breast cancer therapy"],"prefix":"10.1016","volume":"40","author":[{"given":"Chenxi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiye","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilan","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Bing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2021.116185_b0005","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.breast.2015.04.002","article-title":"Breast cancer in very young women: Clinicopathological study of 149 patients \u226425 years old","volume":"24","author":"de Deus Moura","year":"2015","journal-title":"Breast"},{"key":"10.1016\/j.bmc.2021.116185_b0010","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.bmc.2021.116185_b0015","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bmc.2021.116185_b0020","first-page":"438","article-title":"Breast cancer statistics, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bmc.2021.116185_b0025","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/156802606776173483","article-title":"Estrogen receptors as therapeutic targets in breast cancer","volume":"6","author":"Ariazi","year":"2006","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmc.2021.116185_b0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.steroids.2014.06.009","article-title":"The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators","volume":"90","author":"Craig Jordan","year":"2014","journal-title":"Steroids"},{"key":"10.1016\/j.bmc.2021.116185_b0035","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/0008-5472.CAN-17-0985","article-title":"Antiestrogen therapy increases plasticity and cancer stemness of prolactin-induced ERa \u00fe mammary carcinomas","volume":"78","author":"Shea","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2021.116185_b0040","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1021\/acs.jmedchem.5b00054","article-title":"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts","volume":"58","author":"Lai","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116185_b0045","first-page":"27","article-title":"New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus","volume":"9","author":"Paplomata","year":"2013","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.bmc.2021.116185_b0050","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrclinonc.2013.29","article-title":"Emerging targeted agents in metastatic breast cancer","volume":"10","author":"Zardavas","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmc.2021.116185_b0055","first-page":"447s","article-title":"Breast Cancer Endocrine Resistance","volume":"9","author":"Schiff","year":"2003","journal-title":"How Growth Factor Signal Estrogen Receptor Coregul Modul Resp"},{"key":"10.1016\/j.bmc.2021.116185_b0060","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Group, E. B. C. T. C","year":"2011","journal-title":"The Lancet"},{"key":"10.1016\/j.bmc.2021.116185_b0065","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd1031","article-title":"Tamoxifen: A most unlikely pioneering medicine","volume":"2","author":"Jordan","year":"2003","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.bmc.2021.116185_b0070","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0140-6736(94)92692-1","article-title":"Risk of endometrial cancer after tamoxifen treatment of breast cancer","volume":"343","author":"van Leeuwen","year":"1994","journal-title":"The Lancet"},{"key":"10.1016\/j.bmc.2021.116185_b0075","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1126\/science.1068537","article-title":"Molecular determinants for the tissue specificity of SERMs","volume":"295","author":"Shang","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bmc.2021.116185_b0080","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.mrfmmm.2005.02.028","article-title":"Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance","volume":"591","author":"Lewis","year":"2005","journal-title":"Mutat Res - Fund Mole Mech Mutag"},{"key":"10.1016\/j.bmc.2021.116185_b0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1586\/14737140.9.1.51","article-title":"The NSABP study of tamoxifen and raloxifene (STAR) trial","volume":"9","author":"Vogel","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.bmc.2021.116185_b0090","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10549-009-0618-4","article-title":"Women\u2019s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid","volume":"119","author":"Fagerlin","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bmc.2021.116185_b0095","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10549-014-3044-1","article-title":"Long-term cognitive function change among breast cancer survivors","volume":"146","author":"Zheng","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bmc.2021.116185_b0100","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1021\/acsmedchemlett.7b00424","article-title":"Selective estrogen receptor degraders (SERDs): A promising treatment to overcome resistance to endocrine therapy in ER\u03b1-positive breast cancer","volume":"8","author":"Abdel-Magid","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2021.116185_b0105","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ijc.2910550529","article-title":"Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182, 780","volume":"55","author":"Hu","year":"1993","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bmc.2021.116185_b0110","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1056\/NEJMoa1201622","article-title":"Combination anastrozole and fulvestrant in metastatic breast cancer","volume":"367","author":"Mehta","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2021.116185_b0115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3816\/CBC.2005.s.008","article-title":"The history and mechanism of action of fulvestrant","volume":"6","author":"Carlson","year":"2005","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.bmc.2021.116185_b0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40487-017-0046-2","article-title":"A review of fulvestrant in breast cancer","volume":"5","author":"Nathan","year":"2017","journal-title":"Oncol Ther"},{"key":"10.1016\/j.bmc.2021.116185_b0125","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1021\/jm0506773","article-title":"Synthesis and evaluation of estrogen receptor ligands with bridged oxabicyclic cores containing a diarylethylene motif: Estrogen antagonists of unusual structure","volume":"48","author":"Zhou","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116185_b0130","doi-asserted-by":"crossref","first-page":"8692","DOI":"10.1039\/c2ob26531a","article-title":"Bicyclic core estrogens as full antagonists: Synthesis, biological evaluation and structure-activity relationships of estrogen receptor ligands based on bridged oxabicyclic core arylsulfonamides","volume":"10","author":"Zhu","year":"2012","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.bmc.2021.116185_b0135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nchembio.2236","article-title":"Full antagonism of the estrogen receptor without a prototypical ligand side chain","volume":"13","author":"Srinivasan","year":"2017","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2021.116185_b0140","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejmech.2019.03.058","article-title":"Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs)","volume":"172","author":"Li","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2021.116185_b0145","doi-asserted-by":"crossref","first-page":"111605","DOI":"10.1016\/j.ejmech.2019.111605","article-title":"Novel class of 7-Oxabicyclo[2.2.1]heptene sulfonamides with long alkyl chains displaying improved estrogen receptor alpha degradation activity","volume":"182","author":"Hu","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2021.116185_b0150","doi-asserted-by":"crossref","first-page":"67686","DOI":"10.18632\/oncotarget.11891","article-title":"Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline\/taxane-based chemotherapy","volume":"7","author":"Darb-Esfahani","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmc.2021.116185_b0155","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1586\/14737140.8.10.1689","article-title":"MYC in breast tumor progression","volume":"8","author":"Chen","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.bmc.2021.116185_b0160","doi-asserted-by":"crossref","first-page":"T243","DOI":"10.1530\/ERC-16-0360","article-title":"ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy","volume":"23","author":"Elizalde","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.bmc.2021.116185_b0165","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.7150\/ijbs.21635","article-title":"Risk Factors and Preventions of Breast Cancer","volume":"13","author":"Sun","year":"2017","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.bmc.2021.116185_b0170","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/nar\/gkl010","article-title":"BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution","volume":"34","author":"Deng","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmc.2021.116185_b0175","doi-asserted-by":"crossref","first-page":"8155","DOI":"10.1021\/acs.jmedchem.8b00224","article-title":"Novel Hybrid Conjugates with Dual Suppression of Estrogenic and Inflammatory Activities Display Significantly Improved Potency against Breast Cancer","volume":"61","author":"Ning","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116185_b0180","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ejmech.2016.04.029","article-title":"Design, synthesis and evaluation of 6-aryl-indenoisoquinolone derivatives dual targeting ERalpha and VEGFR-2 as anti-breast cancer agents","volume":"118","author":"Tang","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2021.116185_b0185","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.3892\/ijo.2017.3976","article-title":"Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells","volume":"50","author":"McDermott","year":"2017","journal-title":"Int J Oncol"},{"key":"10.1016\/j.bmc.2021.116185_b0190","doi-asserted-by":"crossref","first-page":"111986","DOI":"10.1016\/j.ejmech.2019.111986","article-title":"Antiproliferative activity of diarylnaphthylpyrrolidine derivative via dual target inhibition","volume":"188","author":"Verma","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2021.116185_b0195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12672-017-0294-5","article-title":"A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor kappaB Pathways with Hybrid Drugs for Breast Cancer Therapy","volume":"8","author":"Kastrati","year":"2017","journal-title":"Hormones Cancer"},{"key":"10.1016\/j.bmc.2021.116185_b0200","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1021\/jm400467w","article-title":"Histone deacetylase inhibitors equipped with estrogen receptor modulation activity","volume":"56","author":"Gryder","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116185_b0205","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1021\/acs.jmedchem.5b00099","article-title":"Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer","volume":"58","author":"Tang","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116185_b0210","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.cellsig.2016.11.002","article-title":"Class I histone deacetylases regulate p53\/NF-kappaB crosstalk in cancer cells","volume":"29","author":"Schafer","year":"2017","journal-title":"Cell Signal"},{"key":"10.1016\/j.bmc.2021.116185_b0215","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1073\/pnas.0307708100","article-title":"Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1","volume":"101","author":"Gui","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bmc.2021.116185_b0220","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1038\/sj.onc.1208646","article-title":"Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer","volume":"24","author":"Saji","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.bmc.2021.116185_b0225","first-page":"1677","article-title":"Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer","volume":"25","author":"Park","year":"2011","journal-title":"Oncol Rep"},{"key":"10.1016\/j.bmc.2021.116185_b0230","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.canlet.2014.04.018","article-title":"Estrogen metabolism and breast cancer","volume":"356","author":"Samavat","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bmc.2021.116185_b0235","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1087057113502673","article-title":"High-throughput screening assays for estrogen receptor by using coumestrol, a natural fluorescence compound","volume":"19","author":"Wang","year":"2014","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.bmc.2021.116185_b0240","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1016\/j.bmc.2016.05.019","article-title":"Synthesis and structure-activity relationships of novel hybrid ferrocenyl compounds based on a bicyclic core skeleton for breast cancer therapy","volume":"24","author":"Li","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2021.116185_b0245","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.canlet.2019.10.019","article-title":"Three-dimensional oxabicycloheptene sulfonate targets the homologous recombination and repair programmes through estrogen receptor alpha antagonism","volume":"469","author":"Wu","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bmc.2021.116185_b0250","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12031-015-0690-7","article-title":"C6 Glioma-Secreted NGF and FGF2 Regulate Neuronal APP Processing Through Up-Regulation of ADAM10 and Down-Regulation of BACE1, Respectively","volume":"59","author":"Xie","year":"2016","journal-title":"J Mole Neurosci: MN"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621001930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621001930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:13:33Z","timestamp":1760836413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089621001930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":50,"alternative-id":["S0968089621001930"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116185","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel hybrid conjugates with dual estrogen receptor \u03b1 degradation and histone deacetylase inhibitory activities for breast cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116185"}}